In this randomised multicentre prospective dose-selection phase IIb superiority trial , 133 patients were randomised between doxorubicin ( n = 43 ) , trabectedin ( 3-hour infusion , T3h ) ( n = 47 ) and trabectedin ( 24-hour infusion , T24h ) ( n = 43 ) .